The UCC professor and chief operating officer of AGI is lining up another listing on London's Alternative Investment Market just two months after AGI's successful debut.

Neurocure co-founder Peter Daly said the company, which focuses on "re-purposing" existing drug treatments, will float "within 18 months to two years". Daly said they would look to AIM first but would "probably" seek a listing on Dublin's IEX too.

Neurocure is conducting trials on drugs with potential to treat conditions such as Alzheimer's. It received 850,000 from Dublin venture capital firm Delta in 2004 following its first round of equity fund-raising.